US-based investment firm takes controlling stake in Opella, while France's government moves to ensure the company remains in ...

Sanofi is now in “exclusive ... Opella is a leading supplier of over-the-counter medicines, vitamins, minerals and supplements. Some of its most popular products include the antihistamine ...

Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 ...

Sanofi said it is the third-largest business worldwide in the market for over-the-counter medicines ... production volume for Opella's sensitive products in France," Armand added, including ...

With its decision, Sanofi joined peers Johnson & Johnson, Pfizer and GSK in hiving off businesses that sell over-the-counter medicines ... sell different types of products and services to both ...

including details by product and quarter, are expected to be provided in the coming weeks. After the closing of the transaction, the share of results from the retained minority interest in Opella will ...

However, on October 17, J.P. Morgan maintained a Hold rating on Sanofi (Other OTC: SNYNF ... production and distribution of pharmaceutical products. It operates through the following business ...

which is the third-largest business in the world in the over-the-counter and vitamins, minerals & supplements market, according to Sanofi. The French pharma company said the deal, which saw CD&R ...

The French government has warned the United States investment company buying the consumer healthcare division of drugmaker ...

Sanofi said it is the third-largest business worldwide in the market for over-the-counter medicines ... production volume for Opella's sensitive products in France," Armand added, including ...